Case report: Severe combined immunodeficiency with ligase 1 deficiency and Omenn-like manifestation.
Immunoglobilins
Omenn-like
hematopoietic stem cell transplantation (HCST)
immunodeficiency
ligase 1
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
08
2022
accepted:
03
10
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
9
11
2022
Statut:
epublish
Résumé
DNA ligase I deficiency is an extremely rare primary immunodeficiency with only 6 patients reported in the literature. Most common manifestations include radiosensitivity, macrocytic anemia, lymphopenia with an increased percentage of gamma-delta T cells, and hypogammaglobulinemia requiring replacement therapy. Two-month-old girl with delayed development, T-B-NK+ SCID, and macrocytic anemia presented features of Omenn syndrome. Whole exome sequencing revealed two novel, heterozygous variants (c.2312 G>A, p.Arg771Gly and c.776+5G>T, p.Pro260*) in the LIG1 gene (NM_000234.1). Hematopoietic stem cell transplantation from a fully matched unrelated donor was performed at the age of 4 months using GEFA03 protocol. Mixed donor-recipient chimerism was observed, with 60-70% chimerism in the mononucleated cell compartment and over 90% in T-lymphocyte compartment, but autologous myeloid recovery. Stable CD4+ and CD8+ T-cell counts above 200/µL were achieved after 2 months, but the patient remained transfusion-dependent. Despite satisfactory immunological reconstitution, the second transplantation due to constitutional hemolytic defect has been considered. In light of possible re-transplantation, an issue of optimal conditioning protocol with sufficient myeloid engraftment is important. For the first time Omenn syndrome is described in a compound heterozygote carrying two the novel variants p.Arg771Gly and p.Pro260* in the LIG1 gene. Patients diagnosed with SCID and Omenn syndrome showing macrocytic anemia, should be screened for DNA ligase I deficiency.
Identifiants
pubmed: 36341401
doi: 10.3389/fimmu.2022.1033338
pmc: PMC9626757
doi:
Substances chimiques
DNA Ligase ATP
EC 6.5.1.1
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1033338Informations de copyright
Copyright © 2022 Dabrowska-Leonik, Pastorczak, Bąbol-Pokora, Bernat-Sitarz, Piątosa, Heropolitańska-Pliszka, Kacprzak, Kalwak, Gul, Burg, Ussowicz and Pac.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mutat Res. 1983 Feb;107(2):371-86
pubmed: 6408472
Subcell Biochem. 2012;62:327-41
pubmed: 22918593
Carcinogenesis. 1983;4(5):559-64
pubmed: 6850987
J Clin Invest. 2018 Dec 3;128(12):5489-5504
pubmed: 30395541
Mutagenesis. 2020 Dec 1;35(5):391-404
pubmed: 32914844
Biol Blood Marrow Transplant. 2018 Nov;24(11):2245-2249
pubmed: 30454873
Clin Cancer Res. 2021 Jan 15;27(2):575-584
pubmed: 33082212
Nature. 2004 Nov 25;432(7016):473-8
pubmed: 15565146
Bioinformatics. 2015 Mar 1;31(5):761-3
pubmed: 25338716
Chem Rev. 2006 Feb;106(2):687-99
pubmed: 16464020
Nucleic Acids Res. 2021 Feb 22;49(3):1619-1630
pubmed: 33444456
Klin Padiatr. 2015 May;227(3):157-65
pubmed: 25985449
Lancet. 1992 Jun 20;339(8808):1508-9
pubmed: 1351188
J Clin Immunol. 2021 Jan;41(1):238-242
pubmed: 33025376